B of A Securities analyst Julien Dumoulin-Smith downgrades Black Hills (NYSE:BKH) from Buy to Neutral and announces $66 price target.
Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial
The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized…